UTI delivered robust top-line growth in QQ2 2024, led by double-digit growth in new student starts and continued execution across its multidivisional platform. Consolidated revenue rose 12.4% year over year to $184.2 million, with the UTI division up 14.7% and Concorde up 8.2%. New student starts totaled 5,480, up 18.5% YoY, with the UTI division generating 2,840 starts (up 19.6%) and Concorde 2,640 starts (up 17.2%). Profitability benefited from favorable operating leverage and ongoing cost optimization, producing adjusted EBITDA of $22.6 million, up 17.8% YoY, and net income of $7.8 million (EPS $0.14). Management updated fiscal 2024 guidance higher, targeting 25,500–26,500 starts, $720–$730 million revenue, and $102–$104 million in adjusted EBITDA, with an implied 14.2% midpoint margin. Looking into 2025, the company outlined a longer-term plan aiming for nearly $800 million in revenue and approximately 15% adjusted EBITDA margin, reflecting continued growth, program expansion, and optimization. Notable operational drivers include new program launches (e.g., dental hygiene, phlebotomy, sterile processing), stronger online and blended-learning capabilities, Houston campus unification, and expanded industry partnerships. The company remains vigilant regarding regulatory and macro headwinds (e.g., FAFSA simplification, DoE restrictions on Concorde growth) that could influence cadence but retains a constructive growth trajectory based on demand for skilled trades, healthcare-aligned programs, and an expanding partner ecosystem.